Emergent BioSolutions Inc.
Emergent BioSolutions provides medical countermeasures and commercial products addressing public health threats including chemical, biological, radiological and nuclear agents, emerging infectious diseases, and opioid overdose.
Emergent BioSolutions Inc is a Healthcare company operating in Drug Manufacturers - Specialty & Generic with a $405.0M market cap.
Most recent reported earnings: Q2 FY2026 (Aug 4, 2026).
21 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Disclosures
Extracted from Unknown source, 2026-06-21.
Transcripts
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
History
Spoken Alpha tracks EBS's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Beats consensus 6/10 quarters with 70% positive reaction rate
SampleSpoken Alpha builds an accountability record per executive — how the person's own guidance, language, and reactions have evolved across every call they've appeared on. The one-liners below are illustrative placeholder data pending the deviation v1 work. Click any name for the full role timeline and call appearance history.
Peers
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for EBS.
$ curl https://api.spokenalpha.com/v1/companies/EBSFAQ
Spoken Alpha indexes EBS's earnings call transcripts at https://spokenalpha.com/companies/EBS. Each call links to attributed speakers and parsed analyst Q&A. Emergent BioSolutions Inc.'s own investor relations page is at https://investors.emergentbiosolutions.com/.
Emergent BioSolutions Inc. (EBS) held its most recent earnings call on 2026-05-01, covering fiscal Q1 2026.
Emergent BioSolutions Inc. (EBS) operates in the Healthcare sector (Drug Manufacturers - Specialty & Generic industry).
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2026 | 2026-08-04 | — | $0.11 | — | — | — | — | EODHD |
| Q1 FY2026 | 2026-04-30 | $0.21 | $-0.25 | +100.0% | $156.1M | — | — | EODHD |
| Q4 FY2025 | 2026-03-09 | $-0.43 | $0.42 | -100.0% | $148.7M | — | — | EODHD |
| Q3 FY2025 | 2025-10-28 | $1.06 | $0.05 | +100.0% | $231.1M | — | — | EODHD |
| Q2 FY2025 | 2025-08-05 | $0.16 | $-0.10 | +100.0% | $140.9M | — | — | EODHD |
| Q1 FY2025 | 2025-04-28 | $0.71 | $0.70 | +1.4% | $222.2M | — | — | EODHD |
| Q4 FY2024 | 2025-03-03 | $-0.58 | $-0.50 | -16.5% | $194.7M | — | — | EODHD |
| Q3 FY2024 | 2024-11-05 | $1.37 | $0.14 | +100.0% | $293.8M | — | — | EODHD |
| Q2 FY2024 | 2024-08-05 | $-2.32 | $-0.94 | -100.0% | $254.7M | — | — | EODHD |
| Q1 FY2024 | 2024-04-30 | $0.59 | $-0.86 | +100.0% | $300.4M | — | — | EODHD |
| Q4 FY2023 | 2024-03-05 | $-0.77 | $-0.19 | -100.0% | $276.6M | — | — | EODHD |
| Q3 FY2023 | 2023-11-07 | $-0.54 | $-0.22 | -100.0% | $270.5M | — | — | EODHD |
| Q2 FY2023 | 2023-08-07 | $-1.06 | $-0.49 | -100.0% | $337.9M | — | — | EODHD |
| Q1 FY2023 | 2023-05-08 | $-3.17 | $-1.24 | -100.0% | $164.3M | — | — | EODHD |
| Q4 FY2022 | 2023-02-26 | $-0.31 | $0.04 | -100.0% | $330.7M | — | — | EODHD |
| Q3 FY2022 | 2022-11-07 | $-1.27 | $-0.06 | -100.0% | $239.9M | — | — | EODHD |
| Q2 FY2022 | 2022-07-31 | $-0.86 | $0.38 | -100.0% | $239.9M | — | — | EODHD |
| Q1 FY2022 | 2022-04-27 | $0.18 | $0.13 | +38.5% | $307.5M | — | — | EODHD |
| Q4 FY2021 | 2022-02-23 | $4.50 | $4.27 | +5.4% | $723.2M | — | — | EODHD |
| Q3 FY2021 | 2021-11-03 | $-0.36 | $2.35 | -100.0% | $329.0M | — | — | EODHD |
Source: EODHD. EBS reported actuals as published; sparse fields render as —.
Consistent execution against consensus with the stock following through is the cleanest signal a guidance regime is calibrated. Worth watching for the inflection where execution deteriorates relative to the bar.
Missed in 2 of the last 4 quarters
SampleRecent misses matter more than long-window beat rate — the trailing 12 months drives the analyst model and the next-print bar.
| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $4.54 | $4.45 | +2.0% | +8.4% | +11.2% |
| Q4 FY2026 | $4.21 | $4.45 | -5.4% | +0.5% | +1.1% |
| Q3 FY2026 | $4.56 | $4.63 | -1.6% | -2.5% | -2.0% |
| Q2 FY2026 | $4.88 | $4.58 | +6.6% | +8.8% | +9.0% |
| Q1 FY2025 | $4.62 | $4.57 | +1.0% | +4.8% | +4.9% |
CFO since 2025 • 3/4 beats (75%) • guidance suspended Q3 FY2026
| Q4 FY2025 |
| $4.64 |
| $4.63 |
| +0.2% |
| -0.1% |
| +0.5% |
| Q3 FY2025 | $4.84 | $4.65 | +4.1% | +5.0% | +4.7% |
| Q2 FY2025 | $4.58 | $4.52 | +1.4% | +5.5% | +4.2% |
| Q1 FY2024 | $4.22 | $4.56 | -7.4% | +3.9% | +6.3% |
| Q4 FY2024 | $4.19 | $4.50 | -6.8% | -1.8% | -4.4% |